Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease

被引:4
作者
Galli, Mattia [1 ,2 ]
Rollini, Fabiana [1 ]
Been, Latonya [1 ]
Zenni, Martin M. [1 ]
Angiolillo, Dominick J. [1 ]
Franchi, Francesco [1 ]
机构
[1] Univ Florida, Div Cardiol, Coll Med Jacksonville, 655 West 8th St, Jacksonville, FL 32209 USA
[2] GVM Care & Res, Maria Cecilia Hosp, Cotignola, Italy
关键词
Diabetes mellitus; Antiplatelet therapy; Switching; Prasugrel; Ticagrelor; P2Y(12) inhibitor; Pharmacodynamic; ANTIPLATELET THERAPY; PLATELET INHIBITION; RESPONSIVENESS; REACTIVITY; CANGRELOR; OUTCOMES;
D O I
10.1007/s11239-022-02696-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Switching P2Y(12) inhibitors is common in clinical practice. However, data on the pharmacodynamic (PD) effects of switching in clinical settings characterized by high platelet reactivity, such as diabetes mellitus (DM), are limited. This is a post-hoc analysis from a prospective, randomized, open-label study conducted in coronary artery disease patients comparing the PD effects of loading dose (LD) and maintenance dose regimens of prasugrel vs ticagrelor according to DM status. A total of 110 patients were enrolled: 42 (38%) with DM and 68 (62%) without DM. All patients were on maintenance dual antiplatelet therapy with aspirin and clopidogrel. PD assessments were performed using whole blood vasodilator-stimulated phosphoprotein (VASP), with results quantified by the platelet reactivity index (PRI), VerifyNow P2Y12 (VN-P2Y12) with results reported as P2Y12 reaction units (PRU), and light transmittance aggregometry (LTA) following 20 and 5 mu M adenosine diphosphate stimuli with results reported as maximum platelet aggregation (MPA). PD assessments were performed at baseline (while on clopidogrel), 30 min after LD, 2 h after LD, and 1 week after LD. Overall, platelet reactivity was higher in DM than in non-DM patients while on clopidogrel therapy. After switching to either prasugrel or ticagrelor, platelet reactivity dropped but remained significantly higher among patients with DM at 30 min with all tests (VN-PRU p < 0.01, MPA 20 mu M p < 0.01, VASP-PRI p = 0.02) and at 2 h with VN-PRU (p < 0.01) and LTA-MPA 20 mu M (p < 0.01) but not with VASP-PRI (p = 0.19). There were no significant differences between prasugrel and ticagrelor both among patients with or without DM, except for lower LTA-MPA 20 at 30 min (p < 0.01) among non-DM patients treated with prasugrel. Patients with DM treated with clopidogrel have higher platelet reactivity compared to patients without DM. Although platelet reactivity markedly reduces to a similar extent after switching to prasugrel or ticagrelor, patients with DM persist with increased platelet reactivity compared to patients without DM. Study registration: ClinicalTrials.gov identifier: NCT01852175
引用
收藏
页码:461 / 469
页数:9
相关论文
共 33 条
[1]   Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease [J].
Angiolillo, DJ ;
Fernandez-Ortiz, A ;
Bernardo, E ;
Ramírez, C ;
Sabaté, M ;
Jimenez-Quevedo, P ;
Hernández, R ;
Moreno, R ;
Escaned, J ;
Alfonso, F ;
Bañuelos, C ;
Costa, MA ;
Bass, TA ;
Macaya, C .
DIABETES, 2006, 55 (03) :780-784
[2]   Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease [J].
Angiolillo, Dominick J. ;
Bernardo, Esther ;
Sabate, Manel ;
Jimenez-Quevedo, Pilar ;
Costa, Marco A. ;
Palazuelos, Jorge ;
Hernandez-Antolin, Rosana ;
Moreno, Raul ;
Escaned, Javier ;
Alfonso, Fernando ;
Banuelos, Camino ;
Guzman, Luis A. ;
Bass, Theodore A. ;
Macaya, Carlos ;
Fernandez-Ortiz, Antonio .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (16) :1541-1547
[3]   Antiplatelet therapy after percutaneous coronary intervention [J].
Angiolillo, Dominick J. ;
Galli, Mattia ;
Collet, Jean-Philippe ;
Kastrati, Adnan ;
O'Donoghue, Michelle L. .
EUROINTERVENTION, 2022, 17 (17) :E1371-E1396
[4]   Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel The ABCD-GENE Score [J].
Angiolillo, Dominick J. ;
Capodanno, Davide ;
Danchin, Nicolas ;
Simon, Tabassome ;
Bergmeijer, Thomas O. ;
ten Berg, Jurrien M. ;
Sibbing, Dirk ;
Price, Matthew J. .
JACC-CARDIOVASCULAR INTERVENTIONS, 2020, 13 (05) :606-617
[5]   International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies [J].
Angiolillo, Dominick J. ;
Rollini, Fabiana ;
Storey, Robert F. ;
Bhatt, Deepak L. ;
James, Stefan ;
Schneider, David J. ;
Sibbing, Dirk ;
So, Derek Y. F. ;
Trenk, Dietmar ;
Alexopoulos, Dimitrios ;
Gurbel, Paul A. ;
Hochholzer, Willibald ;
De Luca, Leonardo ;
Bonello, Laurent ;
Aradi, Daniel ;
Cuisset, Thomas ;
Tantry, Udaya S. ;
Wang, Tracy Y. ;
Valgimigli, Marco ;
Waksman, Ron ;
Mehran, Roxana ;
Montalescot, Gilles ;
Franchi, Francesco ;
Price, Matthew J. .
CIRCULATION, 2017, 136 (20) :1955-+
[6]   Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease [J].
Angiolillo, Dominick J. ;
Jakubowski, Joseph A. ;
Ferreiro, Jose Luis ;
Tello-Montoliu, Antonio ;
Rollini, Fabiana ;
Franchi, Francesco ;
Ueno, Masafumi ;
Darlington, Andrew ;
Desai, Bhaloo ;
Moser, Brian A. ;
Sugidachi, Atsuhiro ;
Guzman, Luis A. ;
Bass, Theodore A. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (10) :1005-1014
[7]   Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention [J].
Aradi, Daniel ;
Kirtane, Ajay ;
Bonello, Laurent ;
Gurbel, Paul A. ;
Tantry, Udaya S. ;
Huber, Kurt ;
Freynhofer, Matthias K. ;
ten Berg, Jurrien ;
Janssen, Paul ;
Angiolillo, Dominick J. ;
Siller-Matula, Jolanta M. ;
Marcucci, Rossella ;
Patti, Giuseppe ;
Mangiacapra, Fabio ;
Valgimigli, Marco ;
Morel, Olivier ;
Palmerini, Tullio ;
Price, Matthew J. ;
Cuisset, Thomas ;
Kastrati, Adnan ;
Stone, GreggW. ;
Sibbing, Dirk .
EUROPEAN HEART JOURNAL, 2015, 36 (27) :1762-1771
[8]  
Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI [10.1161/CIR.0000000000000746, 10.1161/CIR.0000000000000659]
[9]   Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54 [J].
Bhatt, Deepak L. ;
Bonaca, Marc P. ;
Bansilal, Sameer ;
Angiolillo, Dominick J. ;
Cohen, Marc ;
Storey, Robert F. ;
Im, Kyungah ;
Murphy, Sabina A. ;
Held, Peter ;
Braunwald, Eugene ;
Sabatine, Marc S. ;
Steg, Ph. Gabriel .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (23) :2732-2740
[10]   Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events [J].
Bhatt, Deepak L. ;
Stone, Gregg W. ;
Mahaffey, Kenneth W. ;
Gibson, C. Michael ;
Steg, P. Gabriel ;
Hamm, Christian W. ;
Price, Matthew J. ;
Leonardi, Sergio ;
Gallup, Dianne ;
Bramucci, Ezio ;
Radke, Peter W. ;
Widimsky, Petr ;
Tousek, Frantisek ;
Tauth, Jeffrey ;
Spriggs, Douglas ;
McLaurin, Brent T. ;
Angiolillo, Dominick J. ;
Genereux, Philippe ;
Liu, Tiepu ;
Prats, Jayne ;
Todd, Meredith ;
Skerjanec, Simona ;
White, Harvey D. ;
Harrington, Robert A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (14) :1303-1313